Analysts’ Weekly Ratings Updates for Abbott Laboratories (ABT)

Several analysts have recently updated their ratings and price targets for Abbott Laboratories (NYSE: ABT):

• 4/17/2025 – Abbott Laboratories had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $145.00 price target on the stock, up previously from $133.00.
• 4/17/2025 – Abbott Laboratories had its price target raised by analysts at Wells Fargo & Company from $136.00 to $147.00. They now have an “overweight” rating on the stock.
• 4/17/2025 – Abbott Laboratories had its price target raised by analysts at Barclays PLC from $158.00 to $159.00. They now have an “overweight” rating on the stock.
• 4/17/2025 – Abbott Laboratories had its price target raised by analysts at Raymond James from $132.00 to $142.00. They now have an “outperform” rating on the stock.
• 4/17/2025 – Abbott Laboratories had its price target raised by analysts at Royal Bank of Canada from $140.00 to $145.00. They now have an “outperform” rating on the stock.
• 4/17/2025 – Abbott Laboratories had its price target raised by analysts at Jefferies Financial Group Inc. from $135.00 to $137.00. They now have a “hold” rating on the stock.
• 4/17/2025 – Abbott Laboratories had its price target raised by analysts at Morgan Stanley from $117.00 to $127.00. They now have an “equal weight” rating on the stock.
• 4/17/2025 – Abbott Laboratories had its price target raised by analysts at Stifel Nicolaus from $135.00 to $145.00. They now have a “buy” rating on the stock.
• 3/10/2025 – Abbott Laboratories had its price target raised by analysts at Bank of America Co. from $133.00 to $150.00. They now have a “buy” rating on the stock.

Abbott Laboratories Stock Performance

NYSE ABT opened at $132.92 on Monday. The stock has a fifty day simple moving average of $130.21 and a 200 day simple moving average of $122.99. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $230.53 billion, a price-to-earnings ratio of 17.38, a PEG ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.78%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 30.61%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Lisa D. Earnhardt sold 91,167 shares of Abbott Laboratories stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the completion of the transaction, the executive vice president now owns 71,928 shares in the company, valued at approximately $9,625,404.96. The trade was a 55.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Sally E. Blount sold 2,600 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the transaction, the director now owns 34,058 shares of the company’s stock, valued at approximately $4,415,960.28. The trade was a 7.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 95,278 shares of company stock valued at $12,745,859 over the last three months. Company insiders own 0.46% of the company’s stock.

Institutional Trading of Abbott Laboratories

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Abbott Laboratories by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 168,645,397 shares of the healthcare product maker’s stock worth $19,075,481,000 after buying an additional 739,260 shares during the last quarter. Capital International Investors lifted its holdings in Abbott Laboratories by 3.4% during the 4th quarter. Capital International Investors now owns 67,972,953 shares of the healthcare product maker’s stock valued at $7,688,160,000 after buying an additional 2,229,026 shares in the last quarter. Capital Research Global Investors boosted its position in Abbott Laboratories by 1.5% in the 4th quarter. Capital Research Global Investors now owns 54,097,005 shares of the healthcare product maker’s stock valued at $6,118,903,000 after buying an additional 795,073 shares during the period. Geode Capital Management LLC grew its stake in Abbott Laboratories by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 35,668,834 shares of the healthcare product maker’s stock worth $4,023,027,000 after acquiring an additional 765,636 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in Abbott Laboratories by 2.3% during the 4th quarter. Wellington Management Group LLP now owns 26,392,302 shares of the healthcare product maker’s stock worth $2,985,233,000 after purchasing an additional 581,325 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.